Uutistiedote

Potilas Lääkäri

IHOSAIRAUDET

Atooppinen ekseema

Hiuspohjan sairaudet

Hyönteisten puremat ja pistot

Sieni-infektiot

ERITYISESTI

Kortikosteroidivoiteet

Potilashistoriat

TIETOA DERMAKLINIKKA.
FI-SIVUSTOTA

Dermaklinikka taustaa

Yhteydenotto Dermaklinikka

Smoke exposure and atopic dermatitis in offspring

Antihypertensive drugs do not cause psoriasis

Safety profile for the use of topical calcineurin inhibitors

Teaching adolescents about acne

Partial matrix excision or orthonyxia for ingrowing toenails

Polymorphic Eruptions in Pregnancy Linked to Male Fetuses

Frequent hand washing by healthcare workers and risk of cont

Malignant melanomas often look different from other moles

Lack of oxygen is probable cause of infant birthmarks

Prevalence of Hand Eczema in Patients with Atopic Dermatitis

Retapamulin - a new treatment of impetigo in children

Smoking increases the Risk of Psoriasis

Minority of children with atopic eczema develop asthma

Allergen of the Year for 2007: Fragrance

Skin Manifestations Common in Young Type 1 Diabetics

Lymphoma risk following calcineurine inhibitors and tropical

Tea consumption associated with reduction of skin cancer

Gene defect plays an important role in the development of ec

Number of life births associated with melanoma risk

Nevi with terminal hair can be malign tumours

Smoking affects skin all over body

The risk of children's eczema can be connected to maternal d

Patients with psoriasis are undertreated

Fungal nails can lead to both tinea pedis and other dermatom

Limited use of potent topical steroids does not affect the h

Tacrolimus Ointment - a safe and effective treatment of atop

Burn injuries do not increase risk of skin cancer

Cutaneous reactions to transdermal therapeutic systems (TTSs

Psoriasis and cardiovascular risk factors

Laser Treatment and Tattoo Removal

Multippelien primaarien melanoomien kehittymisriski

Acne vulgariksen fotodynaaminen hoito

Atooppisen ekseeman kehittymisen ennustavat kliiniset merkit

Childhood Rosacea: Look your young patients in the eye

Relationship between diet and acne

Proactive treatment of atopic dermatitis

Attitudes and knowledge about tanning and behaviour

Enbrel® first and only biologic treatment approved for severe psoriasis in paediatric patients

Turkulainen BioCis Pharma aloittaa lääketutkimukset psoriasiksen hoidossa

Euroopan lääkevirasto suosittelee psoriasis-lääke Raptivan (efalitsumabi) myyntiluvan peruuttamista.

News:

Retapamulin - a new treatment of impetigo in children

Retapamulin offers an alternative treatment of impetigo in children.

Retapamulin inhibits protein synthesis through an interaction with the ribosome.

The drug is indicated for use twice daily for a 5-day period and can be used in treatment of impetigo in patients aged 9 months or older.

Retapamulin was approved on the basis of effectiveness data from a placebo-controlled study comparing it with another antibiotic.

Impetigo is a contagious skin infection that usually produces blisters or sores on the face and hands. It is one of the most common skin infections among kids. It is generally caused by one of two bacteria: group A streptococcus or staphylococcus aureus.

Reference: Accessed 20th of December 2007 on Medscape.com

Web-sisällöntuotantoyritys Prescriba ApS, Fruebjergvej 3, 2100 KBH Ø, Tanska on tuottanut Dermaklinikka.fi-sivuston

Puhelin: + 45 39 17 97 62

Faksi: +45 39 17 97 65

Svusto: www.prescriba.com